Caserta E, Chea J, Minnix M, et al. Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood. 2018;131(7):741-745.

On page 741 in the 15 February 2018 issue, the byline omits the fourth author, Erasmus K. Poku. The byline and author affiliations should read:

Enrico Caserta,^1,2,* Junie Chea,^3,* Megan Minnix,³ Erasmus K. Poku,³ Domenico Viola,^1,2 Steven Vonderfecht,⁴ Paul Yazaki,³ Desiree Crow,³ Jihane Khalife,^1,2 James F. Sanchez,² Joycelynne M. Palmer,⁵ Susanta Hui,⁶ Nadia Carlesso,¹ Jonathan Keats,⁷ Young Kim,⁸ Ralf Buettner,² Guido Marcucci,¹ Steven Rosen,² John Shively,³ David Colcher,³ Amrita Krishnan,² and Flavia Pichiorri^1,2

¹Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope, Duarte, CA; ²Briskin Myeloma Center, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; ³Department of Molecular Immunology and ⁴Center for Comparative Medicine, Beckman Research Institute, City of Hope, Duarte, CA; ⁵Department of Information Sciences, Division of Biostatistics, City of Hope, Duarte, CA; ⁶Department of Radiation Oncology, Beckman Research Institute, City of Hope, Duarte, CA; ⁷Translational Genomics Research Institute, Phoenix, AZ; and ⁸Department of Pathology, City of Hope, Duarte, CA

On page 744, under “Acknowledgments,” in the first sentence of the second paragraph, “the Briskin Myeloma Research Award” should read, “a Steven Gordon and Briskin Family Innovation Grant.”

Also on page 744, under “Authorship,” the second clause of the contribution paragraph should read, “E.C., J.C., M.M., E.K.P., D.V., S.V., J.K., P.Y., Y.K., and R.B. performed the research.” The conflict-of-interest paragraph should read, “A.K. is a consultant for and on the speakers’ bureau of Janssen Pharmaceuticals. The remaining authors declare no competing financial interests.”

The errors have been corrected in the online version, which now differs from the print version.